Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Younger says the Protein Data Bank today holds about 10,000 antibody-antigen structures and adds roughly 1,000 yearly. Their internal scaling work suggests good generalizable de novo design models may need hundreds of thousands to millions of structures, so waiting on PDB growth is far too slow.

Related Insights

To demonstrate industrial-scale viability, Chai Discovery tested its antibody design model on 50 different targets. This focus on generalization, far beyond the typical 2-4 targets shown in academic research, is crucial for proving a model is not a statistical anomaly and is ready for real-world application.

Machine learning's application in multi-specific antibody design is hampered by a lack of public data. Companies must invest heavily in generating their own large-scale, proprietary datasets to train effective models, creating a significant barrier to entry and a competitive advantage.

To break the data bottleneck in AI protein engineering, companies now generate massive synthetic datasets. By creating novel "synthetic epitopes" and measuring their binding, they can produce thousands of validated positive and negative training examples in a single experiment, massively accelerating model development.

The public database of protein structures (PDB) is small and grows slowly. To train more powerful models, Genesis leverages physics simulations to model small molecule behavior, creating a large, high-quality synthetic dataset that isn't possible for more complex protein-protein interactions.

As biologics evolve into complex multi-specific and hybrid formats, the number of design parameters (valency, linkers, geometry) becomes too vast for experimental testing. AI and computational design are becoming essential not to replace scientists, but to judiciously sample the enormous design space and guide engineering efforts.

Current AI for protein engineering relies on small public datasets like the PDB (~10,000 structures), causing models to "hallucinate" or default to known examples. This data bottleneck, orders of magnitude smaller than data used for LLMs, hinders the development of novel therapeutics.

Younger notes the PDB shows how proteins physically interact but not how strongly, and it has almost no examples of antibodies one or two mutations apart with measured affinities. Zero-shot optimization instead needs local affinity landscapes built from many single-point mutation variants across many targets.

Younger says de novo designs currently achieve reasonable single-digit percent success rates only against the easiest targets and epitopes. The field's ambition is to engineer challenging epitopes and additional properties, where success rates remain very low; he argues more and better data are still needed.

Standard co-folding models struggle with induced proximity because public databases like the PDB lack sufficient training data for multi-protein complexes. Because dynamic multi-protein complexes take on endless conformations, standard AI models become overconfident and inaccurate. To solve this, Protai generates proprietary structural proteomics data that maps physical distances and conformations, enabling accurate modeling of complexes that can be targeted by molecular glues and PROTACs.

David Younger says his company's model training showed that solving truly hard protein design problems will require much more data than the field expects. He also warns public binding and affinity data are often not interoperable, lack proper controls, and lack annotations, making them hard to reuse.

PDB's 10,000 antibody structures cannot train generalizable design | RiffOn